Evaluate the Efficacy & Safety of Leronlimab in Patients With Severe or Critical COVID-19

Summary

The purpose of this study was assess the safety and efficacy of leronlimab (PRO 140) administered as weekly subcutaneous injection in subjects with severe or critical COVID-19 disease.

Timeline

Start

2020-04-16

Primary completion

2021-10-24

Completion

2022-06-15

Publications

• Background Welch J, Dean J, Hartin J. Using NEWS2: an essential component of reliable clinical assessment. Clin Med (Lond). 2022 Nov;22(6):509-513. doi: 10.7861/clinmed.2022-0435.

Drugs

Indications